Salarius Pharmaceuticals Adjourns Annual Meeting to December 31, 2025 for Additional Votes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy ?
Source: Globenewswire
- Adjournment of Meeting: Salarius Pharmaceuticals announced that its Annual Meeting scheduled for December 19, 2025, was adjourned due to insufficient voting power, requiring additional votes to meet the 34% quorum threshold.
- Voting Participation: At the time of adjournment, proxies representing approximately 30% of the company's outstanding shares had been submitted, indicating low shareholder engagement that could impact decision-making effectiveness.
- Rescheduled Meeting: The meeting will reconvene on December 31, 2025, at 10:00 a.m. Central Time and will continue to be held virtually, ensuring broader shareholder participation in the voting process.
- Voting Encouragement: The company is urging shareholders as of the record date of October 24, 2025, to vote promptly via the Internet or phone to increase turnout and ensure the meeting proceeds smoothly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
